利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.017 秒)

    Vaccine compositions and methods
    3.
    发明申请
    Vaccine compositions and methods 审中-公开

    公开(公告)号：US20200261509A1

    公开(公告)日：2020-08-20

    申请号：US16862069

    申请日：2020-04-29

    申请人： Mirror Biologics, Inc.

    发明人： Michael Har-Noy

    IPC分类号： A61K35/28 ,  A61K39/00 ,  A61K39/39 ,  C12N5/0783

    摘要： The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious diseases and autoimmune disease are also included.

    Methods for handling biological drugs containing living cells
    4.
    发明公开
    Methods for handling biological drugs containing living cells 审中-公开

    公开(公告)号：US20230226112A1

    公开(公告)日：2023-07-20

    申请号：US18124525

    申请日：2023-03-21

    申请人： Mirror Biologics, Inc.

    发明人： Michael Har-Noy

    IPC分类号： A61K35/17 ,  A61K38/21 ,  B65B1/04

    CPC分类号： A61K35/17 ,  A61K38/217 ,  B65B1/04

    摘要： The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutritive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.

    Methods for handling biological drugs containing living cells
    5.
    发明授权
    Methods for handling biological drugs containing living cells 有权

    公开(公告)号：US11648273B2

    公开(公告)日：2023-05-16

    申请号：US16433659

    申请日：2019-06-06

    申请人： Mirror Biologics, Inc.

    发明人： Michael Har-Noy

    IPC分类号： A61K35/17 ,  A61K38/21 ,  B65B1/04

    CPC分类号： A61K35/17 ,  A61K38/217 ,  B65B1/04

    摘要： The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutritive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.

    Methods and compositions for liquidation of tumors
    6.
    发明申请
    Methods and compositions for liquidation of tumors 有权

    公开(公告)号：US20220273784A1

    公开(公告)日：2022-09-01

    申请号：US17748831

    申请日：2022-05-19

    申请人： Mirror Biologics, Inc.

    发明人： Michael Har-Noy

    IPC分类号： A61K39/00 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21

    摘要： This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors wherever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to liquidation of tumors. The method includes administering priming doses of the therapeutic composition, ablation of a selected tumor lesion along with intratumoral injection of the composition and then infusion of the therapeutic composition. These steps enable the systemic liquidation of tumors secondary to immune cell infiltration and leads to immune-mediated tumor eradication.

    Vaccine comprising allogeneic T-cells
    7.
    发明授权
    Vaccine comprising allogeneic T-cells 有权

    公开(公告)号：US11213576B2

    公开(公告)日：2022-01-04

    申请号：US15003437

    申请日：2016-01-21

    申请人： Mirror Biologics, Inc.

    发明人： Michael Har-Noy

    IPC分类号： A61K39/00 ,  A61P35/00 ,  A61K35/17 ,  A61K9/00 ,  A61K39/39

    摘要： The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected lesion by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue, and then delivering one or more doses of allogeneic cells (e.g., Th1 cells) within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen.

    Method of vaccinating using allogeneic cells
    10.
    发明授权
    Method of vaccinating using allogeneic cells 有权

    公开(公告)号：US11160852B2

    公开(公告)日：2021-11-02

    申请号：US15003447

    申请日：2016-01-21

    申请人： Mirror Biologics, Inc.

    发明人： Michael Har-Noy

    IPC分类号： A61K39/00 ,  A61P35/00 ,  A61K35/17 ,  A61K9/00 ,  A61K39/39

    摘要： The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected lesion by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue, and then delivering one or more doses of allogeneic cells (e.g., Th1 cells) within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen.